Literature DB >> 32127660

Trends in clinical development for PD-1/PD-L1 inhibitors.

Jia Xin Yu, Jeffrey P Hodge, Cristina Oliva, Svetoslav T Neftelinov, Vanessa M Hubbard-Lucey, Jun Tang.   

Abstract

Entities:  

Year:  2020        PMID： 32127660     DOI： 10.1038/d41573-019-00182-w

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  51 in total

Review 1.  NAD+ metabolism and its roles in cellular processes during ageing.

Authors:  Anthony J Covarrubias; Rosalba Perrone; Alessia Grozio; Eric Verdin
Journal:  Nat Rev Mol Cell Biol       Date:  2020-12-22       Impact factor: 94.444

2.  Checking autoimmune genetic risk to stratify immune checkpoint inhibitor responders.

Authors:  Animesh A Sinha
Journal:  Proc Natl Acad Sci U S A       Date:  2020-06-05       Impact factor: 11.205

Review 3.  Enabling the next steps in cancer immunotherapy: from antibody-based bispecifics to multispecifics, with an evolving role for bioconjugation chemistry.

Authors:  Fabien Thoreau; Vijay Chudasama
Journal:  RSC Chem Biol       Date:  2021-10-22

Review 4.  Applying high-dimensional single-cell technologies to the analysis of cancer immunotherapy.

Authors:  Satyen H Gohil; J Bryan Iorgulescu; David A Braun; Derin B Keskin; Kenneth J Livak
Journal:  Nat Rev Clin Oncol       Date:  2020-12-04       Impact factor: 66.675

5.  Discovery of Novel Small-Molecule Inhibitors of PD-1/PD-L1 Interaction via Structural Simplification Strategy.

Authors:  Hongbo Zhang; Yu Xia; Chunqiu Yu; Huijie Du; Jinchang Liu; Hui Li; Shihui Huang; Qihua Zhu; Yungen Xu; Yi Zou
Journal:  Molecules       Date:  2021-06-02       Impact factor: 4.411

6.  18F-AraG PET for CD8 Profiling of Tumors and Assessment of Immunomodulation by Chemotherapy.

Authors:  Jelena Levi; Samuel Goth; Lyna Huynh; Tina Lam; Tony L Huynh; Brailee Schulte; Juliet A Packiasamy
Journal:  J Nucl Med       Date:  2020-11-06       Impact factor: 10.057

7.  An ex vivo tumor fragment platform to dissect response to PD-1 blockade in cancer.

Authors:  Paula Voabil; Marjolein de Bruijn; Lisanne M Roelofsen; Sanne H Hendriks; Simone Brokamp; Marlous van den Braber; Annegien Broeks; Joyce Sanders; Petra Herzig; Alfred Zippelius; Christian U Blank; Koen J Hartemink; Kim Monkhorst; John B A G Haanen; Ton N Schumacher; Daniela S Thommen
Journal:  Nat Med       Date:  2021-07-08       Impact factor: 53.440

Review 8.  The dark side of immunotherapy.

Authors:  Nwanneka Okwundu; Douglas Grossman; Siwen Hu-Lieskovan; Kenneth F Grossmann; Umang Swami
Journal:  Ann Transl Med       Date:  2021-06

9.  Increased frequency of TIGIT+CD73-CD8+ T cells with a TOX+ TCF-1low profile in patients with newly diagnosed and relapsed AML.

Authors:  F Brauneck; F Haag; R Woost; N Wildner; E Tolosa; A Rissiek; G Vohwinkel; J Wellbrock; C Bokemeyer; J Schulze Zur Wiesch; C Ackermann; W Fiedler
Journal:  Oncoimmunology       Date:  2021-06-21       Impact factor: 8.110

10.  Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors.

Authors:  Bart K Chwalisz; James Hillis; Amanda C Guidon; Leeann B Burton; Teilo H Schaller; Anthony A Amato; Allison Betof Warner; Priscilla K Brastianos; Tracey A Cho; Stacey L Clardy; Justine V Cohen; Jorg Dietrich; Michael Dougan; Christopher T Doughty; Divyanshu Dubey; Jeffrey M Gelfand; Jeffrey T Guptill; Douglas B Johnson; Vern C Juel; Robert Kadish; Noah Kolb; Nicole R LeBoeuf; Jenny Linnoila; Andrew L Mammen; Maria Martinez-Lage; Meghan J Mooradian; Jarushka Naidoo; Tomas G Neilan; David A Reardon; Krista M Rubin; Bianca D Santomasso; Ryan J Sullivan; Nancy Wang; Karin Woodman; Leyre Zubiri; William C Louv; Kerry L Reynolds
Journal:  J Immunother Cancer       Date:  2021-07       Impact factor: 13.751
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.